Osteogenesis Imperfecta

01Pathophysiology

Osteogenesis Imperfecta results from defects in the synthesis, structure, or processing of type I collagen, the most abundant structural protein in the human body. Type I collagen is a triple helix formed from two pro-alpha-1 chains (encoded by COL1A1 on chromosome 17) and one pro-alpha-2 chain (encoded by COL1A2 on chromosome 7). This collagen is the principal structural component of bone, skin, tendons, ligaments, dentin, and the sclera of the eye, which is why OI is a multi-system disease and not merely a skeletal problem.

The nature of the collagen defect determines disease severity. In Type I OI (the mildest form), the mutation typically causes a quantitative defect: one COL1A1 allele is nonfunctional (a null allele), so the body produces roughly half the normal amount of structurally normal collagen. Because the collagen that is made is normal in structure, these patients have a milder phenotype. In contrast, Types II, III, and IV are caused by qualitative (structural) defects, most commonly a glycine substitution in the Gly-X-Y repeat of the alpha chain. Glycine is the smallest amino acid and must occupy every third position in the triple helix to allow tight winding. When glycine is replaced by a bulkier amino acid, the triple helix cannot fold properly, resulting in structurally abnormal collagen that is degraded or incorporated into tissues in a dysfunctional state. This is a classic example of a dominant-negative effect, where one abnormal chain disrupts the entire trimeric molecule.

The clinical manifestations follow directly from where type I collagen is found. Bone fragility occurs because the organic matrix of bone (osteoid) is primarily type I collagen; defective collagen leads to thin cortices and reduced bone mineral density, making bones prone to fracture. Blue sclerae result from abnormally thin scleral collagen that allows the underlying choroidal vasculature to show through. Dentinogenesis imperfecta occurs because dentin is rich in type I collagen; defective collagen produces teeth that are translucent, discolored, and prone to chipping. Hearing loss (often conductive, sometimes mixed) develops in adolescence or adulthood due to abnormal ossicle formation and otosclerosis-like changes in the temporal bone. Joint hypermobility and skin fragility reflect the role of type I collagen in ligaments and dermis respectively.

02Classification and Clinical Manifestation

The original Sillence classification (1979) divides OI into four types based on clinical severity and inheritance. More recent classifications have added Types V through XV (often autosomal recessive, involving collagen-modifying genes), but exam questions focus overwhelmingly on Types I through IV.

03Diagnostic Workup

When you encounter a vignette describing a child with unexplained fractures, the first step is always a skeletal survey (plain radiographs). This is the best initial test and will reveal the characteristic pattern of diffuse osteopenia, thin cortices, and fractures at various stages of healing. A hallmark finding on skull films is the presence of Wormian bones, which are small, irregular, extra bones within the cranial sutures caused by defective membranous ossification. While Wormian bones are not exclusive to OI (they can also appear in hypothyroidism, Down syndrome, and cleidocranial dysostosis), their presence in the context of multiple fractures and blue sclerae is highly suggestive.

The next critical step is to exclude metabolic bone disease. Serum calcium, phosphorus, alkaline phosphatase, parathyroid hormone, and 25-hydroxyvitamin D should all be checked. In OI, these values are characteristically normal, because the problem is in collagen structure, not in mineral metabolism. This is a key exam distinction: rickets will show low calcium, low phosphorus, elevated alkaline phosphatase, and elevated PTH, while OI will not.

The most accurate (confirmatory) test is molecular genetic testing for mutations in COL1A1 and COL1A2. This identifies the mutation in roughly 90% of cases and also allows for genetic counseling and prenatal diagnosis in future pregnancies. If genetic testing is negative but clinical suspicion remains high, testing for rarer OI-related genes (IFITM5, SERPINF1, CRTAP, etc.) can be pursued.

A DEXA scan can document low bone mineral density and is useful for monitoring treatment response, but it is not diagnostic on its own. In a vignette, DEXA will support the diagnosis but will not be the answer to "what is the most accurate test."

04Management and Treatment

Acute stabilization centers on appropriate fracture management. When a child with OI presents with a new fracture, treat it with immobilization (splinting, casting) just as you would in any patient, but with an important caveat: minimize the duration of immobilization. Prolonged casting accelerates disuse osteoporosis in an already osteopenic skeleton, creating a vicious cycle of further fractures. Early mobilization is essential.

The cornerstone of long-term management is bisphosphonate therapy. IV pamidronate is the most tested agent in pediatric OI and is the answer most licensing exams expect. The mechanism of action is inhibition of osteoclast-mediated bone resorption, leading to increased bone mineral density, thicker cortices, and a reduced fracture rate. Dosing is typically 1 mg/kg/day given as an IV infusion over three consecutive days every 2 to 4 months. Side effects include first-dose fever and myalgias (an acute-phase reaction), transient hypocalcemia, and with long-term use, a theoretical risk of osteonecrosis of the jaw (rare in children). Zoledronic acid (0.05 mg/kg IV every 6 months) is an alternative with the advantage of less frequent dosing.

Orthopedic intervention is indicated for recurrent fractures or progressive bowing deformities. Intramedullary rodding is the procedure of choice. Telescoping rods (such as Fassier-Duval rods) are placed within the medullary canal of long bones and elongate as the child grows, providing internal support that prevents fractures and corrects alignment. This is a very testable concept: when asked about the next step for a child with recurrent femoral fractures despite bisphosphonate therapy, the answer is intramedullary rodding.

Physical therapy and rehabilitation should be initiated early. Low-impact, weight-bearing exercises and aquatic therapy improve muscle strength, bone density, and functional independence. High-impact activities and contact sports are avoided.

There is currently no cure for OI. Gene therapy and stem cell transplantation remain investigational. The management is supportive and aimed at reducing fracture frequency, maximizing mobility, and preventing complications.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The single most tested "gotcha" with Osteogenesis Imperfecta is its overlap with non-accidental trauma (child abuse). Both conditions can present with multiple fractures at different stages of healing in a young child, and examiners love to test whether you can distinguish them. The trap works both ways. In one version, the vignette describes a child brought in with fractures and the caretaker's explanation does not match the injury pattern, but the child also has blue sclerae, a family history of easy fracturing, and Wormian bones on skull X-ray. A student who is anchored on "multiple fractures in a child equals abuse" will miss OI. In the reverse version, the vignette describes features consistent with abuse (metaphyseal corner fractures, retinal hemorrhages, inconsistent history) and a student who has just learned about OI may incorrectly attribute the injuries to a genetic condition. The key discriminators are the physical exam findings (blue sclerae, dentinogenesis imperfecta), the family history, the radiographic pattern (generalized osteopenia and gracile bones versus focal metaphyseal or posterior rib fractures), and the metabolic labs (normal in OI).

A second common trap is confusing OI with rickets. Both cause fractures and bowed legs in children. The discriminator is simple: in OI, serum calcium, phosphorus, alkaline phosphatase, and PTH are all normal, while in rickets they are abnormal. If a vignette gives you a child with fractures, bowing, and normal metabolic labs, think OI, not rickets.

Finally, remember that Type IV OI can present with normal sclerae. If a vignette describes recurrent fractures, a positive family history, and osteopenia but explicitly states "normal sclerae," do not rule out OI. Blue sclerae are characteristic of Type I, but their absence does not exclude the diagnosis. The core competency being tested is whether you can integrate the full clinical picture (family history, fracture pattern, collagen-related findings, normal metabolic workup) rather than relying on a single physical exam finding as a binary rule-in or rule-out.